For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
This study is being performed to assess the safety, tolerability, and preliminary clinical effects of BVD-523 given orally, twice daily for 21-day cycles, in patients with Acute Myelogenous Leukemia (AML) orMyelodysplastic Syndrome (MDS).
Sat, 11/01/2014 to Mon, 05/01/2017
Bone Marrow Disease(s):
myelodysplastic syndromes (MDS)
Drug: BVD-523 Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle